Tomorrow Investor

teloPR
telo-pr
Telo Genomics Receives Accreditation from College of American Pathologists
Toronto, Ontario–(Newsfile Corp. – April 10, 2024) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) a biotech company developing the industry’s leading telomere technology platform with diagnostic and...
telo-pr
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial
Toronto, Ontario–(Newsfile Corp. – April 2, 2024) – Telo Genomics Corp. (TSXV:...
telo-pr
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
Toronto, Ontario–(Newsfile Corp. – February 13, 2024) – Telo Genomics Corp. (TSXV:...
telo-pr
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US
Toronto, Ontario–(Newsfile Corp. – January 30, 2024) – Telo Genomics Corp. (TSXV:...
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
Toronto, Ontario–(Newsfile Corp. – October 12, 2023) – Telo Genomics Corp. (TSXV:...
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
Toronto, Ontario–(Newsfile Corp. – October 12, 2023) – Telo Genomics Corp. (TSXV:...

Trending

fileName-sanofi-s-type-1-diabetes-drug-wins-eu-panel-recommendation-1763128922048
Sanofi's Type 1 Diabetes Drug Wins EU Panel Recommendation
fileName-walmart-ceo-doug-mcmillon-to-retire-names-insider-john-furner-as-successor-1763129019471
Walmart CEO Doug McMillon to Retire, Names Insider John Furner as Successor
fileName-bristol-myers-j-j-halt-heart-drug-trial-after-interim-analysis-shows-poor-results-1763129107913
Bristol Myers, J&J Halt Heart Drug Trial After Interim Analysis Shows Poor Results

CATEGORIES

SIGNUP TO OUR NEWSLETTER

Subscribe

Get breaking market insights directly to your inbox